Evolution of Wet AMD Treatment Options

Video

Roger A. Goldberg, MD, MBA, discusses the evolution of therapy from pre– to post–anti-VEGF agents for patients with wet AMD.

John W. Kitchens, MD: Roger, can you describe the evolution of therapy from pre–anti-VEGF to post–anti-VEGF?

Roger A. Goldberg, MD, MBA: I’d be happy to, although I feel blessed. One of the things that got me excited about becoming an ophthalmologist and a retina specialist was watching the development of these agents in medical school. By the time I was a resident, we were using a lot of off-label Avastin, or bevacizumab, and had the first agents FDA approved. Before that, perhaps some of my older colleagues on the call could speak to what they used to do. Sometimes they would see a choroidal neovascular membrane, or a net as Lloyd called it, and you could laser it. What the laser did is, it cauterized those blood vessels and stopped them from leaking. The downside was the laser induced a scar, so patients would lose vision acutely where the macula was lasered, including sometimes right at the fovea, right at the center of the macula, and patients would drop their vision acutely forever. On average, they would be better than they would have been had they just watched it for the next 2 years, where they would have lost their central vision and then some. They would have lost even more vision. Laser was a mainstay of treatment.

There was a little window where we used photodynamic therapy, or PDT, and in that therapy, you infuse a light-sensitive dye into the vein. Then you’d activate it, not with a hot or thermal laser, but with a cold laser, and that dye would get soaked up in the choroidal neovascular membrane. You can cause regression of those vessels with PDT. PDT helped slow some of the rapid vision loss of wet AMD, and in a subtype of patients with wet AMD [age-related macular degeneration], it wasn’t good for all of them. Then starting around 2006, we had the first FDA approval, so it’s been at least 15 years since the dawn of anti-VEGF agents. There was Macugen [pegaptanib], which was a weaker anti-VEGF agent, that came out a few years before that. Those really have been the mainstay of treatment now, as you said, for 2 decades.

John W. Kitchens, MD: It’s not a hard limb to go out on to say that the anti-VEGF therapies are the gold standard, and we use them in 99%-plus of our cases of exudative age-related macular degeneration. It’s been a tremendous game-changer for us.

I want to thank everyone for watching this HCPLive® Peer Exchange. If you enjoyed the content, please subscribe to our e-newsletters to receive upcoming Peer Exchanges and other great content right in your inbox.

Transcript Edited for Clarity

Recent Videos
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
A panel of 3 experts on dry eye
Viability of Elamipretide for Geographic Atrophy in Dry AMD | Image Credit: HCPLive
Advancing Elamipretide into Phase 3 ReNEW and ReGAIN Trials | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.